Skip to main content
An official website of the United States government

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Trial Status: active

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.